Home › Calculator › ASPHF Dividend Calculator 2026
ASPHF Dividend DRIP Calculator 2026
44.15% YieldHealthcareAscentage Pharma Group International · OTC
Price: $4.53 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When ASPHF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your ASPHF snowball 📈
$10,000 in ASPHF → $15.46M in 10 years · $555.33/month
About Ascentage Pharma Group International (ASPHF) — Dividend Analysis 2026
Ascentage Pharma Group International (ASPHF) is a clinical-stage biotechnology firm that develops novel therapeutic agents. Its primary focus areas include oncological conditions, chronic hepatitis B (HBV), and age-related diseases, with operations concentrated in the United States and Mainland China. A cornerstone of its pipeline is HQP1351, a BCR-ABL inhibitor specifically engineered to combat BCR-ABL mutants, including those bearing the challenging T315I mutation. This compound is particularly aimed at individuals suffering from chronic phase chronic myeloid leukemia (CML) that has proven resistant to conventional tyrosine kinase inhibitor (TKI) treatments. Ascentage's diverse pipeline further includes APG-2575, an orally administered selective Bcl-2 inhibitor currently in Phase Ib/II clinical studies for hematologic malignancies and solid tumors. Another asset is APG-115, an oral small molecule designed to disrupt the MDM2-p53 protein-protein interaction, also intended for solid tumors and blood cancers. Additionally, APG-1387, a small molecule inhibitor of apoptosis proteins, is being developed for advanced solid tumors and chronic HBV infection. Beyond these, Ascentage is actively advancing APG-1252, a small molecule drug engineered to induce apoptosis by selectively inhibiting Bcl-2 and Bcl-xL proteins, targeting small cell lung cancer (SCLC), lymphoma, and various other solid tumors. Other ongoing projects include APG-2449 for non-small-cell lung carcinoma, and APG-5918, a promising orally available and selective EED inhibitor with best-in-class potential, currently in the preclinical stage. Furthermore, APG-265 is in IND-enabling studies for hematological and solid malignancies, while UBX1967/1325, aimed at the Bcl family for diabetic macular edema (DME), is undergoing Phase II development. The company maintains strategic collaboration agreements with prominent biotechnology and pharmaceutical enterprises, as well as respected academic institutions. Notable partners include Innovent Biologics, Inc., the National Cancer Institute, Pfizer Inc., and Clover Biopharmaceuticals (Hong Kong) Co., Limited. Founded in 2009, Ascentage Pharma's corporate headquarters are situated in Suzhou, China.
Compare ASPHF with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full ASPHF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ASPHF position with:
🌍 ASPHF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold ASPHF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 44.15% | 41.35% | $4,415 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 37.53% | 34.73% | $3,753 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 35.32% | 32.52% | $3,532 / yr |
| 🇬🇧 UK ISA | 0% | 44.15% | 41.35% | $4,415 / yr |
| 🇬🇧 UK Taxable | 8.75% | 40.29% | 37.49% | $4,029 / yr |
| 🇨🇦 TFSA | 0% | 44.15% | 41.35% | $4,415 / yr |
| 🇨🇦 CA Taxable | 25% | 33.11% | 30.31% | $3,311 / yr |
| 🇦🇺 Super (pension) | 15% | 37.53% | 34.73% | $3,753 / yr |
| 🇦🇺 AU Taxable | 30% | 30.90% | 28.10% | $3,091 / yr |
| 🇩🇪 DE Taxable | 26.375% | 32.51% | 29.71% | $3,251 / yr |
| 🇫🇷 FR Taxable | 30% | 30.90% | 28.10% | $3,091 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 ASPHF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 ASPHF Dividend Payment Schedule
ASPHF pays quarterly — 4 times per year. Next ex-div: TBD.
📊 ASPHF vs Healthcare Benchmarks
How ASPHF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ASPHF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ ASPHF Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ASPHF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Ascentage Pharma Group International (ASPHF) is currently trading at $4.53, 57% below its 52-week high. The current dividend yield is 44.15% based on an annual payout of $2.00 per share.
ASPHF (Ascentage Pharma Group International) — 44.15% Dividend Yield Analysis
Ascentage Pharma Group International (ASPHF) is a healthcare stock currently trading at $4.53 with a dividend yield of 44.15%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (44.15%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.